Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: A meta-analysis

Journal of Diabetes and its Complications

Volumn 28, Issue 6, 2014, Pages 880-886

  Charbonnel, Bernard ^a   Bertolini, Monica ^b   Tinahones, Francisco J ^c   Domingo, Manuel Puig ^d   Davies, Melanie ^e  

^a HÔTEL DIEU   (France)

^b SANOFI   (France)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Basal insulin; Combination; Lixisenatide; Meta analysis; Prandial

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BASAL INSULIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIXISENATIDE; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; LONG ACTING INSULIN; PEPTIDE; ZP10A PEPTIDE;

ADD ON THERAPY; ARTICLE; BODY MASS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE EFFECTS; AGED; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84908334613     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.07.007     Document Type: Article

References (41)

1. B. Ahrén, D.A. Leguizamo, P. Miossec, S. Saubadu, and R. Aronson Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) Diabetes Care 36 2013 2543 2550
2. American Diabetes Association Standards of medical care in diabetes-2013 Diabetes Care 36 Suppl. 1 2013 S11 S66
3. S. Arnolds, S. Dellweg, J. Clair, M.P. Dain, M.A. Nauck, and K. Rave Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study Diabetes Care 33 2010 1509 1515
4. A. Avignon, A. Radauceanu, and L. Monnier Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes Diabetes Care 20 1997 1822 1826
5. M. Bodmer, C. Meier, S. Krahenbuhl, S.S. Jick, and C.R. Meier Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis Diabetes Care 31 2008 2086 2091
6. M.M. Bonafede, A. Kalsekar, M. Pawaskar, K.M. Ruiz, A.M. Torres, and K.R. Kelly Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: A retrospective database analysis BMC Endocrine Disorders 11 2011 3
7. M. Bouma, J.H. Dekker, J.J. de Sonnaville, F.E. van der Does, H. de Vries, and D.M. Kriegsman How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes? Diabetes Care 22 1999 904 907
8. J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis, and A.Y. Kwan Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial Annals of Internal Medicine 154 2011 103 112
9. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
10. M.A. Crespo, L.C. González Matías, M.G. Lozano, S.F. Paz, M.R. Pérez, and E.V. Gago Gastrointestinal hormones in food intake control [Article in Spanish] Endocrinología y Nutrición 56 2009 317 330
11. P.E. Cryer, S.N. Davis, and H. Shamoon Hypoglycemia in diabetes Diabetes Care 26 2003 1902 1912
12. Diamant M, Nauck M, Shaginian R, Malone, J., Cleall, S., de Vries, D., et al. Exenatide BID vs insulin lispro TIDM added to titrated insulin glargine QD in metformin-treated T2DM patient resulted in similar glycemic control but weight loss and less hypoglycemia: The 4B study. Abstract presented at the 73rd Scientific Sessions of the American Diabetes Association, June 21-25, 2013; Chicago, IL; http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=795037e5-ca6e-44a8-8b54-cfb1400cd733&cKey=f35d109e-da62-4d3c-a9a1-a9dd25395a9f&mKey=%7b89918D6D-3018-4EA9-9D4F-711F98A7AE5D%7d. Last accessed May 27 2014.
13. European Medicines Agency European Public Assessment Report: Lyxumia http://www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-Publicassessmentreport/human/002445/WC500140449.pdf 2012 (Last accessed May 27 2014)
14. F. Farrokhi, O. Klindukhova, P. Chandra, L. Peng, D. Smiley, and C. Newton Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes Journal of Diabetes Science and Technology 6 2012 1022 1029
15. V.A. Fonseca, R. Alvarado-Ruiz, D. Raccah, G. Boka, P. Miossec, and J.E. Gerich Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 35 2012 1225 1231
16. Y. Gao, K.H. Yoon, L.M. Chuang, V. Mohan, G. Ning, and S. Shah Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea Diabetes Research and Clinical Practice 83 2009 69 76
17. A.J. Garber, M.J. Abrahamson, J.I. Barzilay, L. Blonde, Z.T. Bloomgarden, and M.A. Bush American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary Endocrine Practice 19 2013 536 557
18. R.R. Holman, A.J. Farmer, M.J. Davies, J.C. Levy, J.L. Darbyshire, and J.F. Keenan Three-year efficacy of complex insulin regimens in type 2 diabetes New England Journal of Medicine 361 2009 1736 1747
19. J.J. Holst The physiology of glucagon-like peptide 1 Physiological Reviews 87 2007 1409 1439
20. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
21. C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, and A. Hincelin-Méry Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes, Obesity & Metabolism 15 2013 642 649
22. J.L. Leahy Insulin therapy in type 2 diabetes mellitus Endocrinology and Metabolism Clinics of North America 41 2012 119 144
23. J.J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nature Reviews Endocrinology 8 2012 728 742
24. Meier, J.J., Rosenstock J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., et al (2014). Effect of lixisenatide vs. liraglutide on glycemic control, gastric emptying, and safety parameters in optimized insulin glargine T2DM ± metformin. Diabetes, 63 (Suppl. 1):A262 (Abstract 1017-P).
25. U.A. Nayak, J. Govindan, V. Baskar, D. Kalupahana, and B.M. Singh Exenatide therapy in insulin-treated type 2 diabetes and obesity QJM 103 2010 687 694
26. P.S. Odegard, and K. Capoccia Medication taking and diabetes: A systematic review of the literature The Diabetes Educator 33 2007 1014 1029
27. D.R. Owens, S.D. Luzio, C. Sert-Langeron, and M.C. Riddle Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: A 6-month 'proof-of-concept' study Diabetes, Obesity & Metabolism 13 2011 1020 1027
28. M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, and P. Miossec Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 36 2013 2489 2496
29. M.C. Riddle, T. Forst, R. Aronson, L. Sauque-Reyna, E. Souhami, and L. Silvestre Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 36 2013 2497 2503
30. M.C. Riddle, and J. Rosenstock Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086
31. M. Riddle, G. Umpierrez, A. DiGenio, R. Zhou, and J. Rosenstock Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes Diabetes Care 34 2011 2508 2514
32. J. Rosenstock, M. Hanefeld, P. Shamanna, K.W. Min, G. Boka, and P. Miossec Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S) Journal of Diabetes and its Complications 28 2014 386 392
33. J. Rosenstock, D. Raccah, L. Korányi, L. Maffei, G. Boka, and P. Miossec Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 36 2013 2945 2951
34. J. Rosenstock, H.W. Rodbard, S.C. Bain, D. D'Alessio, J. Seufert, and A.B. Thomsen One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA target Journal of Diabetes and its Complications 27 2013 492 500 10.1016/j.jdiacomp.2013.04.008
35. D. Russell-Jones, and R. Khan Insulin-associated weight gain in diabetes-causes, effects and coping strategies Diabetes, Obesity & Metabolism 9 2007 799 812
36. L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, and M.J. de Boer Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) European Heart Journal 28 2007 88 136
37. Y. Seino, K.W. Min, E. Niemoeller, and A. Takami EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes, Obesity & Metabolism 14 2012 910 917
38. S. Soonthornpun, C. Rattarasarn, R. Leelawattana, and W. Setasuban Postprandial plasma glucose: A good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels Diabetes Research and Clinical Practice 46 1999 23 27
39. The Diabetes Control and Complications Trial Research Group Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group American Journal of Medicine 90 1991 450 459
40. B. Verges The impact of prandial glucose regulation in practice Diabetes, Nutrition & Metabolism 15 2002 28 32
41. U. Werner, G. Haschke, A.W. Herling, and W. Kramer Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes Regulatory Peptides 164 2010 58 64